• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Femasys Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/17/25 9:22:13 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care
    Get the next $FEMY alert in real time by email
    false000133900500013390052025-06-172025-06-17

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 17, 2025

    Femasys Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    001-40492
    11-3713499
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)

    3950 Johns Creek Court, Suite 100
    Suwanee, Georgia  30024
    (Address of principal executive offices)

    (770) 500-3910
    (Registrant’s telephone number, including area code)

    n/a
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Exchange Act:
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each
    exchange
    on which registered
    Common Stock, par value $0.001 per share
     
    FEMY
     
    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒



    Item 8.01
    Other Events

    On June 17, 2025, Femasys Inc. (the “Company”) issued a press release announcing the appointment of Ms. Nicholas as its Chief Commercial Officer. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 9.01
    Financial Statements and Exhibits.

    (d)
    Exhibits.

    Exhibit
    No.
    Description
       
    99.1
    Press Release of Femasys Inc. dated June 17, 2025.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Femasys Inc.
     
    By:
    /s/ Kathy Lee-Sepsick
     
    Names: Kathy Lee-Sepsick
     
    Title: Chief Executive Officer
    Date: June 17, 2025
     



    Get the next $FEMY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FEMY

    DatePrice TargetRatingAnalyst
    7/13/2021$18.00Buy
    JonesTrading
    7/13/2021$25.00Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

      -- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® for first-line intratubal insemination treatment and FemVue® for diagnostic evaluation. "Securing regulatory approvals in Australia and New Zealand mark another important step in expand

      7/1/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

      ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) of the Class III FemBloc blended polymer component, marking the first regulatory approval in the world for the FemBloc® System for non-surgical female permanent birth control. After European Medicines Agency (EMA) review, the Notified Body has granted CE mark certification. The regulatory approval for the blended

      6/25/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

      --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

      6/17/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Nicholas Kelley Stinson

      4 - FEMASYS INC (0001339005) (Issuer)

      7/1/25 4:57:48 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • New insider Nicholas Kelley Stinson claimed ownership of 125 shares (SEC Form 3)

      3 - FEMASYS INC (0001339005) (Issuer)

      7/1/25 4:54:34 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Silverman Joshua

      4 - FEMASYS INC (0001339005) (Issuer)

      6/27/25 5:25:24 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    SEC Filings

    See more
    • Femasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      7/3/25 5:22:54 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form S-3 filed by Femasys Inc.

      S-3 - FEMASYS INC (0001339005) (Filer)

      7/3/25 5:19:58 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      7/1/25 9:20:38 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JonesTrading initiated coverage on Femasys with a new price target

      JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

      7/13/21 11:41:28 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Chardan Capital initiated coverage on Femasys with a new price target

      Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

      7/13/21 8:04:59 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

      --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

      6/17/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

      ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here. Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu, M.D. will focus on the current treatment options in the inf

      3/21/24 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

      -- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a contin

      2/6/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Financials

    Live finance-specific insights

    See more
    • Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

      -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update. Corporate Highlights from 1Q 2025 to date Announced FemBloc permanent birth control delivery syste

      5/8/25 5:01:00 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

      -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

      3/27/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

      ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

      11/12/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Femasys Inc.

      SC 13D - FEMASYS INC (0001339005) (Subject)

      11/22/23 4:00:15 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care